Custom service

Ascite Fluid based Antibody Production

Milligrams from a mouse, when in vitro culture will not deliver.

Volume: 5–10 mL — ascites per mouseConcentration: 1–10 mg/mL — specific IgGTimeline: 3–5 weeks — from vial to purified IgG

Ascites production is the oldest method for obtaining monoclonal antibodies in quantity, and it remains the most concentrated crude source available. A mouse primed with an incomplete adjuvant and injected with 5×10⁶ hybridoma cells develops ascites within ten to fourteen days, and the fluid contains 1–10 mg/mL of monoclonal IgG alongside host antibodies, lipids and proteases.

Its advantage is concentration. Where a hybridoma grows poorly in vitro and yields 10 µg/mL in culture, the same clone may yield several milligrams per millilitre in ascites, which makes a small batch feasible without process development. Its disadvantages are equally real: the product is contaminated with mouse immunoglobulins that must be removed, the method involves animal use with associated ethical and regulatory constraints, and it does not scale beyond a few mice.

Purification is not optional. Protein A or G capture separates the monoclonal IgG from most host antibody, but an isotype-matched mouse IgG contaminant can persist and is removed by ion exchange or by affinity purification on the antigen. Each lot is tested for mouse IgG content and for the presence of host antibodies against the target, which would confound any assay using the reagent.

Service Highlights

Where it fits

Ascites is useful when the quantity needed is modest, the clone grows poorly in vitro, and the destination is research use rather than a regulated product. It is also a practical route for antibodies that lose productivity after prolonged culture, since fresh cells are injected directly into the animal.

It is unsuitable for anything intended for human use in most jurisdictions, for diagnostics requiring a documented and reproducible process, and for antibodies whose isotype is difficult to separate from host immunoglobulin. For those, in vitro production with a defined process is the appropriate route.

Documentation and QC

Each lot is delivered with ascites volume, total protein, specific IgG concentration, SDS-PAGE purity, residual mouse IgG content and binding activity. Animal ethics approval documentation and health monitoring records are available on request.

Frequently asked questions

Is ascites still permitted?

For research use it remains permitted in many countries, subject to institutional animal ethics approval. It is not accepted for products intended for human or veterinary therapeutic use, and some funding bodies restrict it.

How do you remove host antibodies?

Protein A capture removes most of them, but an isotype-matched host IgG can co-purify. An ion exchange step or antigen-affinity purification reduces it below 5%, measured by ELISA against mouse IgG.

What if we cannot use animals?

Hollow-fibre bioreactors reach comparable concentrations without animal use, typically 1–5 mg/mL in the harvest. We offer both routes and will quote the one that fits your constraints.

Tell us the quantity and the intended use. If the antibody is destined for a regulated application, we will propose in vitro production instead, because ascites will not satisfy the documentation.

Service Highlights

  • High-concentration crude. 1–10 mg/mL specific antibody, ten- to hundred-fold more concentrated than typical culture supernatant.
  • Pristane or incomplete adjuvant priming. Priming improves yield and consistency; both protocols are run under an approved animal ethics framework.
  • Host IgG removal. Protein A/G capture followed by ion exchange or antigen-affinity purification to reduce mouse IgG background.
  • Lot documentation. Volume, cell inoculum, days to onset, total protein and specific IgG concentration recorded per mouse.
  • Isotype-specific considerations. Mouse IgG1 binds protein A weakly; protein G or an anti-mouse IgG1 affinity step is used instead.
  • Alternative offered. Where regulatory or ethical requirements exclude ascites, hollow-fibre culture is proposed as an equivalent route.

How the work runs

  1. Animal and clone preparation

    Six- to eight-week-old BALB/c mice are primed, and hybridoma cells are expanded to log phase with viability above 90% before injection.

  2. Injection and monitoring

    5×10⁶ cells injected intraperitoneally; animals are monitored daily for ascites development and for signs of distress, with defined humane endpoints.

  3. Harvest

    Ascites collected at maximal distension, typically day 10–14, with a second collection where the animal remains well.

  4. Clarification

    Fluid is clotted at room temperature, centrifuged, and filtered through 0.45 µm; lipid is removed by centrifugation or a depth filter.

  5. Purification

    Protein A or G capture, then ion exchange or antigen affinity to remove host IgG, followed by buffer exchange.

  6. QC

    Purity by SDS-PAGE, mouse IgG content by ELISA, endotoxin, and binding activity against the target.

Specifications & timeline

Volume
5–10 mL — ascites per mouse
Concentration
1–10 mg/mL — specific IgG
Timeline
3–5 weeks — from vial to purified IgG
Yield
5–10 mL ascites per mouse, 1–10 mg/mL specific IgG
Mice per batch
5–20, according to the quantity required
Timeline
3–5 weeks from cell vial to purified IgG
Purification
Protein A/G, ion exchange, antigen affinity
Purity
>90% by SDS-PAGE after purification; host IgG below 5%
Deliverables
10 mg–1 g purified IgG, lot record, SDS-PAGE, host IgG content, binding data

Related Products

Next step

Tell us the target, we will tell you what is feasible

Send the sequence, assay format and sensitivity you need. You will get a technical assessment — recommended platform, timeline and the risks worth knowing before you commit budget.